A very interesting paper from Dr. Mark Davis’ group shows that in response to the mRNA vaccine, CD8 T cell responses are attenuated in people who had prior COVID compared to uninfected people. What does this mean? (1/)
Fei Gao, @VMallajosyula et al used SARS-CoV-2 pMHC-spheromers to detect viral antigen-specific CD8 and CD4 T cells from people who were vaccinated, infected or both. Spheromers are peptide-MHC multimers (12 units) that are more sensitive than conventional pMHC tetramers. (2/)
CD8 T cell responses to viral antigens were compared in people who received the mRNA vaccines to those with prior infection with SARS-CoV-2. The vaccine induced significantly better CD8 T cell immunity in both quantity and quality than the infection. (3/)
Notably, people who recovered from COVID and then were vaccinated had much lower CD8 T cell response than people who were not infected (naive) and vaccinated. The CD8 T cells’ ability to secrete cytokines and become activated was also poorer in the recovered group. (4/)
Why does infection induce poorer CD8 T cell immunity than the vaccine? The answer may be related to the ability of this virus to impair MHC I presentation (5/)
Why does prior infection impair CD8 T cell responses induced by the mRNA vaccine? This may imply induction of some form of regulatory immune response by the infection, or sequestration of Spike by preexisting antibodies for MHC I presentation. (6/)
Does this mean that prior infection with COVID will render people susceptible to future reinfections? Not necessarily. We know that prior infection promotes better neutralizing antibody responses after vaccination - the best correlate of protection. (7/)
Does the study by Gao et al mean that prior COVID will make people immunodeficient (unable to fight any infection)? Not likely based on other data. @JohngLab found enhanced (not lower) immunity to flu vaccine in men who recovered from mild COVID. (8/)
Could impaired CD8 T cell immunity lead to long COVID? Possibly - by enabling the SARS-CoV-2 infection to persist or by enabling reinfections to be more productive. But this hypothesis must be tested. A great paper with much to think about. (End)
Very excited that our PaxLC clinical trial on #longCOVID patients is now open, led by @hmkyale! This is a phase 2, 1:1 randomized, double-blind, placebo-controlled research study in 100 non-hospitalized highly symptomatic long COVID. (1/)
We will be providing paxlovid or placebo pills in long haulers for 15 days. The primary outcome will be measured by asking the patients to fill out some questionnaires pre & post treatment. We will find out whether their health changes with paxlovid vs. placebo. (2/)
Before, during, and after treatment, we will do a deep dive immune profiling to see if any changes are detected due to Paxlovid. We will apply a similar strategy that we used in our study with @PutrinoLab to understand the immune and viral signatures (3/)
Does the innate immune system recognize metastatic cells and control their growth?
@weizmano et al found that type 2 dendritic cells and natural killer cells orchestrate very early immunity against metastatic cancer cells in the lung 👇🏽 (1/)
Adaptive immune system is important to ultimately eliminate cancer cells. However, what happens in the first days after metastatic cells arrive in a target tissue? @weizmano looked at the first 3 days after metastasis and found leukocyte recruitment around the cancer cell. (2/)
Next, @weizmano used various mice with depletion in dendritic cell types and found that CD11b+ dendritic cells (but not monocytes, CD301b+, or DC1) were required to contain the rapid growth of metastatic cells. (3/)
A while ago, @MiyuMoriyama et al showed that SARS-CoV-2 variants suppress MHC I levels in infected cells to the same degree as the ancestral virus. Then came the Omicron variants. A short update. (1/) biorxiv.org/content/10.110…
Since the original submission, @MiyuMoriyama, with the help of @NathanGrubaugh's team & @carolilucas, obtained and analyzed the ability of Omicron subvariants shown here 👇🏽 Miyu gated on spike-positive (infected) cells and compared MHC I levels to uninfected (S-) cells. (2/)
Note that MHC I surface levels are only downregulated in the infected (S+) cells, but not in the uninfected cells (S-) in the same tissue culture wells. SARS-CoV-2 evades recognition of the infected cells by cytotoxic T cells but has no impact on the surrounding cells. (3/)
Very excited to share our latest research on immunological features of #LongCovid. Our 2+ year collaboration with @PutrinoLab with many other fantastic colleagues and patients - Mount Sinai Yale Long COVID (MY-LC) study by @sneakyvirus1 et al. 🧵(1/)
There are multiple hypotheses behind long COVID pathogenesis including persistent virus/viral remnants, autoimmunity, dysbiosis, virome reactivation and tissue damage. Our data will dive deep into some of these. (3/)
A brilliant & timely review by Prof. #DianeEGriffin on the persistence of viral RNA following RNA virus infection - which can be associated with late progressive disease or nonspecific lingering symptoms of post-acute infection syndromes (#PAIS). (1/)
First question addressed is WHERE viral RNA can persist. After a variety of RNA virus infection, viral RNA can persist not only in immune privileged sites (brain, eyes, and testes), but also in blood, lymphoid tissue, joints, respiratory tract, GI tissues, and kidney. (2/)
Consequences of persistent viral RNA may include organ-specific as well as nonspecific postviral syndromes such as long COVID, post-Ebola, and post-polio syndromes, characterized by symptoms including fatigue, headache, muscle pain, and joint pain. (3/)
With millions of #longCOVID patients, it is becoming better known that even a mild infection can lead to longterm debilitating health problems. SARS-CoV-2 joins the long list of other pathogens that cause post-acute infection syndrome (PAIS). (2/)
What are some common and distinct symptoms associated with PAIS? Strikingly, there are a number of shared symptoms such as excertion intolerance, fatigue, pain, neurological symptoms..etc. Others are more unique to the pathogen that triggered the disease. (3/)